SGB-3403

N/A

Report date: 2023/12/08 15:26:10
NME

Base Information

Drug NameSGB-3403
Drug Alias NameSGB-3403
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipidemias +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSuzhou Sanegene Bio Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Sanegene Bio Inc
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipidemias +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A